Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period

This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for modification must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2021 National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third party codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2021 American Medical Association. LOINC(R) copyright 2004-2021 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2021 International Health Terminology Standards Development Organisation. ICD-10 copyright 2021 World Health Organization. All Rights Reserved.

The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
 
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

Report a total score, and each of the following strata:
Stratum 1: Patients age 16-20 by the end of the measurement period
Stratum 2: Patients age 21-24 by the end of the measurement period

None

None

Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in roughly 1.7 million cases (Centers for Disease Control and Prevention, 2019). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (U.S. Preventive Services Task Force, 2014; Centers for Disease Control and Prevention, 2019). 

Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (Centers for Disease Control and Prevention, 2019).

U.S. Preventive Services Task Force (2014) recommends screening for chlamydia in sexually active females aged 24 years or younger and in older women who are at increased risk for infection (B recommendation)

Higher score indicates better quality

Reference Type: CITATION

Reference Text: 'Centers for Disease Control and Prevention (CDC). (2019). Sexually Transmitted Disease Surveillance 2018. Atlanta: U.S. Department of Health and Human Services.'

Reference Type: CITATION

Reference Text: 'LeFevre, M. L., & U.S. Preventive Services Task Force. (2014). Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 161(12), 902–910. https://doi.org/10.7326/M14-1981'

None

Codes to identify sexually active women include codes for: pregnancy, sexually transmitted infections, contraceptives or contraceptive devices, and infertility treatments.

The denominator exclusion does not apply to patients who qualify for the initial population (IP) based on services other than the pregnancy test alone. These other services include services for sexually transmitted infections, contraceptives or contraceptive devices and infertility treatments. For example, a patient who has both a pregnancy test and a chlamydia diagnosis, either of which would qualify them for the IP, would not be eligible for this denominator exclusion.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

TBD

Women 16 to 24 years of age by the end of the measurement period who are sexually active and who had a visit in the measurement period

Equals Initial Population

Women who are only eligible for the initial population due to a pregnancy test and who had an order for an x-ray or for a specified medication within 7 days of the pregnancy test.

Exclude patients who are in hospice care for any part of the measurement period.

Women with at least one chlamydia test during the measurement period

Not Applicable

None

For every patient evaluated by this measure also identify payer, race, ethnicity and sex